Latest News & Article

Tag: disease

CHAI: Saving Lives and Reducing Disease Burden in Low- and Middle-Income Countries
Health

CHAI: Saving Lives and Reducing Disease Burden in Low- and Middle-Income Countries


2024-02-15 21:14:41 The Clinton Health Access Initiative, Inc. (CHAI) is a global health organization committed to saving lives and reducing the burden of disease in low- and middle-income countries. We work at the invitation of governments to help them and the private sector create and maintain high-quality health systems. CHAI was founded in 2002 in … Read more
You can read the full story here: CHAI: Saving Lives and Reducing Disease Burden in Low- and Middle-Income Countries.

Daewoong Pharmaceutical’s Fexuclu: A Global Success Story
Business

Daewoong Pharmaceutical’s Fexuclu: A Global Success Story

Daewoong Pharmaceutical’s 34th domestically produced new drug, ‘Fexuclu’, is expanding rapidly globally. Daewoong Pharmaceutical announced on the 16th that Fexuclu, a treatment for gastroesophageal reflux disease, has entered the market or is about to enter the market in 24 countries, including Korea, just one year and six months on after launch. As of February 2024, […]
The post Daewoong Pharmaceutical’s Fexuclu: A Global Success Story appeared first on News Directory 3.

ChatGPT: A Promising Tool for Predicting Cardiovascular Disease
Health

ChatGPT: A Promising Tool for Predicting Cardiovascular Disease

[팜뉴스=김태일 기자] Yonsei University College of Medicine Yongin Severance Hospital (director Kim Eun-kyung), Professor Bae Seong-ah of the Department of Cardiology, and Professor Yoon Deok-yong of the Department of Biomedical Systems Information (co-first authors Han Chang-ho, Kim Dong-won and Kim Song-soo) demonstrated the accuracy of ChatGPT in predicting cardiovascular disease. Recently, large-scale language models like […]
The post ChatGPT: A Promising Tool for Predicting Cardiovascular Disease appeared first on News Directory 3.

Hanmi Pharmaceutical and Green Cross, developing new drugs for Fabry disease, how competitive are they?
Business

Hanmi Pharmaceutical and Green Cross, developing new drugs for Fabry disease, how competitive are they?

You can read the full story here: Hanmi Pharmaceutical and Green Cross, developing new drugs for Fabry disease, how competitive are they?.
2024-02-15 22:02:35 Sanofi-Aventis Korea’s Fabry disease treatment ‘Fabrazyme’ product image. Screenshot of homepage. The development of a treatment for Fabry disease by Hanmi Pharmaceutical and GC Green Cross is on track. Both companies aim to develop new drugs with longer-lasting effects than existing treatments. Hanmi Pharmaceutical and GC Green Cross conducted a non-clinical trial of … Read more